Amenamevir Production Cost Reports

The report provides a detailed analysis essential for establishing an Amenamevir manufacturing plant. It encompasses all critical aspects necessary for Amenamevir production, including the cost of Amenamevir production, Amenamevir plant cost, Amenamevir production costs, and the overall Amenamevir manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Amenamevir production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Amenamevir is a novel kind of antiviral drug used to treat infections such as shingles and chickenpox caused by the varicella-zoster virus, and genital herpes and cold sores caused by the herpes simplex virus. It works by stabilizing the bond between the viral protein's primase and helicase and their target DNA. By preventing these proteins from fulfilling their functions in the life cycle of the virus, this action stops the virus from proliferating and spreading. Amenamevir aids in the management of infections brought on by these viruses by interfering with the mechanism that permits the virus to proliferate.

The procurement of Amenamevir is influenced by its application in the pharmaceutical and medical industries as an antiviral medication used to treat viral infections. The use of Amenamevir has been demanded more since cases of viral infections are rising. Compared to acyclovir, a typical antiviral medication, it has been demonstrated to have greater antiviral activity. Amenamevir 200 mg and 400 mg were shown to be as effective and well-tolerated for treating shingles as valaciclovir standard treatment in a clinical investigation.

Since the majority of adverse effects are minimal, it is considered a good substitute for conventional antiviral drugs. Valaciclovir and acyclovir require three and five daily dose schedules, respectively, Amenamevir needs to be administered once daily, which increases patient adherence. For patients with herpes zoster, Amenamevir is a good substitute for nucleoside antiviral medications in treatment. Overall, industrial Amenamevir procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of viral infections, better tolerability, fewer side effects, increased efficacy, enhanced patient adherence, and regulatory approvals.

Raw Material for Amenamevir Production

According to the Amenamevir manufacturing plant project report, the key raw material used in the production of Amenamevir includes 1,1-dioxothiane-4-carboxylic Acid.

Manufacturing Process of Amenamevir

The extensive Amenamevir production cost report consists of the following major industrial manufacturing process:

• Production from 1,1-dioxothiane-4-carboxylic Acid: The manufacturing process of Amenamevir starts with the reaction of 1,1-dioxothiane-4-carboxylic Acid with oxalyl chloride and subsequent nucleophilic addition with aniline to form an amide intermediate. Finally, the amide intermediate undergoes N-alkylation, ester hydrolysis, and amidation reaction to form Amenamevir.

Amenamevir, commercially known as Amenalief, appears as a white to off-white powder having the molecular formula C24H26N4O5S and a molecular weight of 482.6 g/mol. It has a water solubility of 0.123 mg/mL. It has a log P value of 2.03. The value of its dissociation constant, pKa, is 12.19. Amenamevir is a new helicase-primase inhibitor that works against both types 1 and 2 of the herpes simplex virus and varicella-zoster virus. Amenamevir disrupts viral DNA replication and growth by stabilizing the helicase-primase's connection with its DNA substrates and blocking the enzyme's advancement through helicase or primase catalytic cycles.